What Negative Roxadustat FDA AdCom Vote Means for Fibrogen's (FGEN) Stock?
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
FibroGen (FGEN) PT Lowered to $16 at Cowen
July 16, 2021 6:47 AM EDTCowen analyst Yaron Werber lowered the price target on FibroGen (NASDAQ: FGEN) to $16.00 (from $21.00) while maintaining a Market Perform rating following negative AdCom.
The analyst commented, "Given the votes against approving roxadustat in either CKD anemia segment, we are removing US sales and... More
FibroGen (FGEN) PT Lowered to $18 at Mizuho Securities on Negative AdCom Vote
July 16, 2021 6:26 AM EDTMizuho Securities analyst Difei Yang lowered the price target on FibroGen (NASDAQ: FGEN) to $18.00 (from $32.00) while maintaining a Neutral rating on negative AdCom vote.
The analyst commented, "We are lowering our US PoS for roxadustat to 0% from 50% and lowering ex-US roxadustat sales estimates following... More
BofA Securities Downgrades FibroGen (FGEN) to Neutral
July 16, 2021 6:10 AM EDTBofA Securities analyst Jason Gerberry downgraded FibroGen (NASDAQ: FGEN) from Buy to Neutral with a price target of $29.00.
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $24.84 yesterday.
... MoreUPDATE: Stifel Downgrades FibroGen (FGEN) to Hold
July 16, 2021 2:29 AM EDT(Updated - July 16, 2021 3:57 AM EDT)
Stifel analyst Annabel Samimy downgraded FibroGen (NASDAQ: FGEN) from Buy to Hold with a price target of $29.00 (from $55.00).
The analyst comments "We downgrade FGEN to Hold on the negative outcome for the Roxadustat AdCom. The panel overwhelmingly... More
FibroGen (FGEN) Says FDA Advisory Committee Voted to Recommend Not Approving Roxadustat
July 15, 2021 6:34 PM EDTFibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. The Committee based its recommendation on data from a global Phase 3... More
FibroGen (FGEN) Halted, News Pending
July 15, 2021 6:55 AM EDTFibroGen (NASDAQ: FGEN) Halted, News Pending
